AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22025196 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 45 mg 6-month depot
Number of subjects: 151
Study 22025453 — intervention group
Group type: EXPERIMENTAL
Intervention: DGCR8, AGO1, AGO2, PACT, TARBP1 mRNA expression levels in AK, BCC, and SCC groups
Number of subjects: 28
Study 22025453 — intervention group
Group type: EXPERIMENTAL
Intervention: TARBP2 mRNA expression levels in AK, BCC, and SCC groups
Number of subjects: 28
Study 22025778 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of crown-like structures (CLS) in subcutaneous adipose tissue (n = 16)
Number of subjects: 36
Study 22026962 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-based HAART (Nevirapine and Efavirenz)
Number of subjects: 107
Study 22027439 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected Walking Impairment Questionnaire (WIQc)
Number of subjects: 310
Study 22027439 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected Estimated Ambulatory Capacity by History Questionnaire (EACH-Qc)
Number of subjects: 310
Study 22027439 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Impairment Questionnaire (WIQ)
Number of subjects: 310
Study 22027439 — intervention group
Group type: COMPARATOR
Intervention: Maximal Walking Time (MWT) on treadmill
Number of subjects: 310
Study 22027845 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 968
Study 22027845 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 968
Study 22027845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 22028492 — intervention group
Group type: EXPERIMENTAL
Intervention: L19-IL2 in combination with dacarbazine
Number of subjects: 29
Study 22028948 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 190
Study 22029910 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 113
Study 22029910 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 113
Study 22029981 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet
Number of subjects: 50
Study 22030215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a constant rate for the first 12 hours, then titrated between 0.1 and 2.5 μg/kg/h for up to 14 days.
Number of subjects: 13
Study 22030222 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 1 (lowest) of 25(OH)D concentrations
Number of subjects: 2429
Study 22030222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of 25(OH)D concentrations with normal waist circumference
Number of subjects: 2429
Study 22030222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of 25(OH)D concentrations with abdominal obesity
Number of subjects: 2429
Study 22030252 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP-health literacy scale (HBP-HLS)
Number of subjects: 386
Study 22030751 — intervention group
Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 17
Study 22030751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 17
Study 22030751 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, carboplatin, nanoparticle albumin-bound paclitaxel, methotrexate
Number of subjects: 17
Study 22030975 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing 14.5 ml of water
Number of subjects: 0
Study 22030975 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing 20 ml of water
Number of subjects: 0
Study 22030975 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing 100 ml of water
Number of subjects: 0
Study 22030975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest condition
Number of subjects: 0
Study 22031059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesofacial, brachyfacial, and dolichofacial subjects
Number of subjects: 78
Study 22031059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolichofacial subjects
Number of subjects: 78
Study 22031059 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 78
Study 22031271 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) combined with gait training and body weight support (BWS)
Number of subjects: 12
Study 22031271 — intervention group
Group type: COMPARATOR
Intervention: Ground level gait training using BWS
Number of subjects: 12
Study 22032709 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1603
Study 22032709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1603
Study 22032709 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1C
Number of subjects: 1603
Study 22032709 — intervention group
Group type: COMPARATOR
Intervention: Rate
Number of subjects: 1603
Study 22032711 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR(CT)
Number of subjects: 103
Study 22032711 — intervention group
Group type: COMPARATOR
Intervention: CCTA stenosis
Number of subjects: 103
Study 22033282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 110 mg, administered orally three times per week
Number of subjects: 51
Study 22033282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 85 mg, administered orally three times per week
Number of subjects: 51
Study 22033282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 110 mg
Number of subjects: 51
Study 22033282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocetinostat 85 mg
Number of subjects: 51
Study 22033322 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 75 mg/m(2) administered once weekly until disease progression or intolerance
Number of subjects: 52
Study 22033322 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 22033493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential azacitidine and lenalidomide
Number of subjects: 18
Study 22033636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg/bid continuously and 5-fluorouracil 200 mg/sqm/daily day 1-14 every 3 weeks
Number of subjects: 39
Study 22033636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus 5-fluorouracil
Number of subjects: 39
Study 22033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid arterial strain
Number of subjects: 10407
Study 22033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial distensibility
Number of subjects: 10407
Study 22033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffness indices
Number of subjects: 10407
Study 22033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-strain
Number of subjects: 10407
Study 22033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Young elastic moduli
Number of subjects: 10407
Study 22033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial compliance
Number of subjects: 10407
Study 22033999 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10407
Study 22034223 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 232
Study 22034233 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent septoplasty during endoscopic sinus surgery (ESS) (n = 108)
Number of subjects: 221
Study 22034233 — intervention group
Group type: COMPARATOR
Intervention: No septoplasty during endoscopic sinus surgery (ESS) (n = 113)
Number of subjects: 221
Study 22034233 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent septoplasty during endoscopic sinus surgery (ESS)
Number of subjects: 221
Study 22035077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker
Number of subjects: 406
Study 22035077 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 406
Study 22035077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker upgrade to ICD
Number of subjects: 406
Study 22035077 — intervention group
Group type: EXPERIMENTAL
Intervention: Device patients
Number of subjects: 406
Study 22035417 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan consolidation treatment after R-CHOP chemotherapy
Number of subjects: 21
Study 22035573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese study group
Number of subjects: 301
Study 22035573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 22035648 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 49
Study 22035806 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m(2)) and carboplatin (AUC=6.0-7.5) every 21 days for 3 doses, followed by radiation therapy, followed by an additional 3 cycles of paclitaxel and carboplatin (AUC=5-6)
Number of subjects: 81
Study 22036135 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR ≥ 2.8 (75th percentile cutoff)
Number of subjects: 262
Study 22036135 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid ≥ 5.0 mg/dL
Number of subjects: 262
Study 22036634 — intervention group
Group type: EXPERIMENTAL
Intervention: bosutinib therapy
Number of subjects: 288
Study 22037543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual temperature measurement
Number of subjects: 171
Study 22037543 — intervention group
Group type: COMPARATOR
Intervention: Tympanic temperature measurement
Number of subjects: 171
Study 22038032 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal surgery
Number of subjects: 94
Study 22038032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 22038064 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss therapy for 1 year
Number of subjects: 57
Study 22039246 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation
Number of subjects: 20
Study 22039493 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI cut-off points for glycaemia factor
Number of subjects: 1333
Study 22039493 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI cut-off points for lipid factor
Number of subjects: 1333
Study 22039493 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI cut-off points for blood pressure factor
Number of subjects: 1333
Study 22039493 — intervention group
Group type: EXPERIMENTAL
Intervention: WC cut-off points for glycaemia factor
Number of subjects: 1333
Study 22039493 — intervention group
Group type: EXPERIMENTAL
Intervention: WC cut-off points for lipid factor
Number of subjects: 1333
Study 22039493 — intervention group
Group type: EXPERIMENTAL
Intervention: WC cut-off points for blood pressure factor
Number of subjects: 1333
Study 22040109 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MNC as a cell therapy product
Number of subjects: 11
Study 22040109 — intervention group
Group type: COMPARATOR
Intervention: CLI patients
Number of subjects: 11
Study 22040109 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MNC
Number of subjects: 11
Study 22043118 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation (HGNS)
Number of subjects: 21
Study 22044606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m(2) and carboplatin AUC 6
Number of subjects: 66
Study 22044927 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche high-sensitive cTnT (hs-cTnT)
Number of subjects: 401
Study 22044927 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens cTnI-Ultra
Number of subjects: 401
Study 22044927 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott-Architect cTnI
Number of subjects: 401
Study 22044927 — intervention group
Group type: COMPARATOR
Intervention: Standard assay (Roche cTnT)
Number of subjects: 401
Study 22044927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive cTn assays
Number of subjects: 401
Study 22045986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of a TLR9 agonist combined with radiation
Number of subjects: 15
Study 22046855 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (outreach via tailored letters, automated and personal phone calls, point-of-care prompts)
Number of subjects: 469
Study 22046855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening promotion intervention)
Number of subjects: 469
Study 22047558 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 (a small-molecule dimerizing drug)
Number of subjects: 5
Study 22048109 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine
Number of subjects: 230
Study 22048718 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA) titrated daily for a maximum of 72 hours.
Number of subjects: 15
Study 22048718 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy volunteers, 14 participants.
Number of subjects: 15
Study 22049179 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-negative feedback on LH in AAW
Number of subjects: 23
Study 22049179 — intervention group
Group type: COMPARATOR
Intervention: E2-negative feedback on LH in CW
Number of subjects: 23
Study 22049179 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-negative feedback on FSH in AAW
Number of subjects: 23
Study 22049179 — intervention group
Group type: COMPARATOR
Intervention: E2-negative feedback on FSH in CW
Number of subjects: 23
Study 22049179 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-positive feedback on LH in AAW
Number of subjects: 23
Study 22049179 — intervention group
Group type: COMPARATOR
Intervention: E2-positive feedback on LH in CW
Number of subjects: 23
Study 22049179 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-positive feedback on FSH in AAW
Number of subjects: 23
Study 22049179 — intervention group
Group type: COMPARATOR
Intervention: E2-positive feedback on FSH in CW
Number of subjects: 23
Study 22050371 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV) at individualized doses (1,000-4,000 mg/day; 20-80 mg/kg/day for children/adolescents weighing <50 kg)
Number of subjects: 217
Study 22050371 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV)
Number of subjects: 217
Study 22050987 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine albumin to creatinine ratio categories (≤ 10 mg/g, 11-29 mg/g, 30-299 mg/g, ≥ 300 mg/g)
Number of subjects: 1159
Study 22050987 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine albumin to creatinine ratio added to clinical model
Number of subjects: 1159
Study 22050987 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine albumin to creatinine ratio
Number of subjects: 1159
Study 22051872 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 104
Study 22051930 — intervention group
Group type: COMPARATOR
Intervention: Baseline ventilator settings on the first night
Number of subjects: 8
Study 22051930 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted ventilator settings under PSG on the second night
Number of subjects: 8
Study 22052198 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-driven treatment (fixed metformin and glargine, insulin adjusted according to sliding scale)
Number of subjects: 99
Study 22052198 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemic management
Number of subjects: 99
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m(2) orally for 7 days every 4 weeks (methylated MGMT - mMGMT)
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 100 mg/m(2) orally for 14 days followed by 200 mg/m(2) orally for 7 days every 6 weeks (unmethylated MGMT - unMGMT)
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (both mMGMT and unMGMT)
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high HCT-CI scores
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow blast count <50% at screening
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) among responders
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of response among responders
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction deaths (ID)
Number of subjects: 36
Study 22052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematological toxicities
Number of subjects: 36
Study 22052690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (720 EI.U of HAV and 20 µg of HBsAg)
Number of subjects: 306
Study 22052690 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent hepatitis B vaccine (additional dose)
Number of subjects: 306
Study 22052917 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem 20 million
Number of subjects: 25
Study 22052917 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem 50 million
Number of subjects: 25
Study 22052917 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiStem 100 million
Number of subjects: 25
Study 22052917 — intervention group
Group type: COMPARATOR
Intervention: Registry control group
Number of subjects: 25
Study 22054035 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD subjects with exacerbations within 30 days of the 3-month visit
Number of subjects: 201
Study 22054035 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 201
Study 22054035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 201
Study 22054223 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (BOTOX®)
Number of subjects: 609
Study 22054243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 26
Study 22054243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22055846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide and cisplatin sandwiched with RT
Number of subjects: 27
Study 22055846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide alone sandwiched with RT
Number of subjects: 27
Study 22056301 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest generation wide-angle, high-definition colonoscopes
Number of subjects: 1256
Study 22056301 — intervention group
Group type: COMPARATOR
Intervention: Routine equipment (mixed older technology endoscopes)
Number of subjects: 1256
Study 22056381 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 treatment
Number of subjects: 0
Study 22056644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 26
Study 22057876 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of plaque instability (MPO, MRP-8/14, PAPP-A, CRP)
Number of subjects: 398
Study 22057876 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO, MRP-8/14, CRP
Number of subjects: 398
Study 22057876 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal and high-sensitivity cardiac troponin T)
Number of subjects: 398
Study 22058200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day (days 1-21 of each 28-day cycle) and dexamethasone (40 mg/day on days 1, 8, 15, and 22) for up to 12 months
Number of subjects: 33
Study 22058217 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20-positive patients
Number of subjects: 172
Study 22058217 — intervention group
Group type: COMPARATOR
Intervention: CD20-negative patients
Number of subjects: 172
Study 22058220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere length measured by automated multicolor flow fluorescence in situ hybridization in peripheral blood leukocyte subsets.
Number of subjects: 65
Study 22058220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocytes alone for clinical screening.
Number of subjects: 65
Study 22058220 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow fluorescence in situ hybridization for telomere length measurement.
Number of subjects: 65
Study 22058220 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow up of dyskeratosis congenita patients.
Number of subjects: 65
Study 22058220 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted telomere length values.
Number of subjects: 65
Study 22058220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere length measurement.
Number of subjects: 65
Study 22058224 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count in the first quartile on treatment day 33
Number of subjects: 256
Study 22058224 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count above the median on day 8
Number of subjects: 256
Study 22058224 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet counts after induction treatment
Number of subjects: 256
Study 22058224 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease-based risk group distribution
Number of subjects: 256
Study 22058223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem transplants (double autologous transplant or a single autologous transplant followed by an allogeneic transplant)
Number of subjects: 80
Study 22067102 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily insulin regimen with long acting insulin analogue (LAIA) at dinner
Number of subjects: 18
Study 22067102 — intervention group
Group type: COMPARATOR
Intervention: Three times daily insulin regimen (standard TID regimen)
Number of subjects: 18
Study 22067102 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily insulin regimen with LAIA at dinner
Number of subjects: 18
Study 22067397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 12.5 mg administered as a 30-minute intravenous infusion once daily for 5 days every 2 weeks
Number of subjects: 212
Study 22067400 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait-and-see policy (cCR group)
Number of subjects: 21
Study 22067400 — intervention group
Group type: COMPARATOR
Intervention: Pathologic complete response (pCR group)
Number of subjects: 21
Study 22067707 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPP (Screening Inventory of Psychosocial Problems) screening procedure
Number of subjects: 268
Study 22068254 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment (subcutaneous injections once or twice daily)
Number of subjects: 55
Study 22068586 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCA3 mutations identified in patients
Number of subjects: 47